DC-CIK治疗晚期非小细胞肺癌的近期临床疗效观察

Clinical efficacy of DC-CIK treatment for advanced non-small cell lung cancer

目的评价树突状细胞(dendritic cell,DC)联合细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效及安全性。方法收集34例采用DC-CIK细胞治疗可评价的晚期NSCLC患者,评价其近期疗效及安全性。结果 DC-CIK细胞治疗晚期NSCLC 1-3月后的客观缓解率(objective response rate,ORR)为20.6%,疾病控制率(disease control rate,DCR)为67.6%。近期疗效与远处转移无关(P>0.05)。患者细胞治疗的ORR与治疗次数无关(P>0.05),DCR与治疗次数有关(P<0.05)。无明显的不良反应。结论 DC-CIK治疗晚期NSCLC安全、有效,可减缓病情进展,为晚期NSCLC患者提供了一条新的治疗途径。

Objective To evaluate the safety and clinical efficacy of dendritic cell （ DC ） -cytokine induced killer cell （CIK） treatment for advanced non-small cell lung cancer（NSCLC）. Methods Thirty-four NSCLC patients treated with DC-CIK were eligible for evaluation. The clinical efficacy, immune function, quality of life and toxicity were evaluated. Results The objective response rate （ORR） was 20.6% and the disease control rate （DCR） was 67.6% after 1 -3 months of treatment. The ORR and DCR were not correlated with the status of metastasis （ P 〉 0.05 ）. The number of DC-CIK treatment was not correlated with the ORR （ P 〉 0.05 ）, but it was correlated with the DCR （ P 〈 0.05 ）. No notable side effects were observed. Conclusion Treatment with DC-CIK cells is safe and effective for advanced NSCLC, and it can also improve quality of life and reduce the probability of metastasis and recurrence for patients.